vs
PATHWARD FINANCIAL, INC.（CASH）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
PATHWARD FINANCIAL, INC.的季度营收约是再鼎医药的1.4倍（$173.1M vs $127.1M），再鼎医药同比增速更快（17.1% vs -0.2%），PATHWARD FINANCIAL, INC.自由现金流更多（$104.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -18.0%）
Pathward Financial, Inc.是一家总部位于美国的银行及金融服务企业，其前身为Meta金融集团旗下相关业务主体，2022年母公司将“Meta”商标出售给Meta Platforms后，正式启用现有名称。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CASH vs ZLAB — 直观对比
营收规模更大
CASH
是对方的1.4倍
$127.1M
营收增速更快
ZLAB
高出17.4%
-0.2%
自由现金流更多
CASH
多$130.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-18.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $173.1M | $127.1M |
| 净利润 | $35.2M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 24.6% | -54.6% |
| 净利率 | 20.3% | — |
| 营收同比 | -0.2% | 17.1% |
| 净利润同比 | 11.9% | — |
| 每股收益（稀释后） | $1.57 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CASHZLAB
| Q4 25 | $173.1M | $127.1M | ||
| Q3 25 | $186.7M | $115.4M | ||
| Q2 25 | $195.8M | $109.1M | ||
| Q1 25 | $274.8M | $105.7M | ||
| Q4 24 | $182.6M | $108.5M | ||
| Q3 24 | $179.5M | $101.8M | ||
| Q2 24 | $188.6M | $100.1M | ||
| Q1 24 | $257.6M | $87.1M |
净利润CASHZLAB
| Q4 25 | $35.2M | — | ||
| Q3 25 | $38.8M | $-36.0M | ||
| Q2 25 | $42.1M | $-40.7M | ||
| Q1 25 | $75.0M | $-48.4M | ||
| Q4 24 | $30.0M | — | ||
| Q3 24 | $33.5M | $-41.7M | ||
| Q2 24 | $44.9M | $-80.3M | ||
| Q1 24 | $69.9M | $-53.5M |
毛利率CASHZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CASHZLAB
| Q4 25 | 24.6% | -54.6% | ||
| Q3 25 | 25.9% | -42.3% | ||
| Q2 25 | 24.1% | -50.3% | ||
| Q1 25 | 33.2% | -53.3% | ||
| Q4 24 | 19.8% | -62.6% | ||
| Q3 24 | 20.9% | -66.6% | ||
| Q2 24 | 27.1% | -76.0% | ||
| Q1 24 | 33.8% | -80.7% |
净利率CASHZLAB
| Q4 25 | 20.3% | — | ||
| Q3 25 | 20.8% | -31.2% | ||
| Q2 25 | 21.5% | -37.3% | ||
| Q1 25 | 27.3% | -45.8% | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 18.7% | -40.9% | ||
| Q2 24 | 23.8% | -80.2% | ||
| Q1 24 | 27.1% | -61.4% |
每股收益（稀释后）CASHZLAB
| Q4 25 | $1.57 | $-0.05 | ||
| Q3 25 | $1.69 | $-0.03 | ||
| Q2 25 | $1.81 | $-0.04 | ||
| Q1 25 | $3.14 | $-0.04 | ||
| Q4 24 | $1.23 | $-0.09 | ||
| Q3 24 | $1.34 | $-0.04 | ||
| Q2 24 | $1.78 | $-0.08 | ||
| Q1 24 | $2.74 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $331.2M | $689.6M |
| 总债务越低越好 | $33.5M | — |
| 股东权益账面价值 | $854.5M | $715.5M |
| 总资产 | $7.6B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.04× | — |
8季度趋势，按日历期对齐
现金及短期投资CASHZLAB
| Q4 25 | $331.2M | $689.6M | ||
| Q3 25 | $120.6M | $717.2M | ||
| Q2 25 | $258.3M | $732.2M | ||
| Q1 25 | $254.2M | $757.3M | ||
| Q4 24 | $597.4M | $779.7M | ||
| Q3 24 | $158.3M | $616.1M | ||
| Q2 24 | $298.9M | $630.0M | ||
| Q1 24 | $347.9M | $650.8M |
总债务CASHZLAB
| Q4 25 | $33.5M | — | ||
| Q3 25 | $33.5M | — | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $33.4M | — | ||
| Q4 24 | $33.4M | — | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $33.4M | — |
股东权益CASHZLAB
| Q4 25 | $854.5M | $715.5M | ||
| Q3 25 | $858.0M | $759.9M | ||
| Q2 25 | $819.0M | $791.7M | ||
| Q1 25 | $814.7M | $810.8M | ||
| Q4 24 | $758.3M | $840.9M | ||
| Q3 24 | $822.5M | $667.7M | ||
| Q2 24 | $748.4M | $704.2M | ||
| Q1 24 | $719.5M | $762.2M |
总资产CASHZLAB
| Q4 25 | $7.6B | $1.2B | ||
| Q3 25 | $7.2B | $1.2B | ||
| Q2 25 | $7.2B | $1.2B | ||
| Q1 25 | $7.0B | $1.2B | ||
| Q4 24 | $7.6B | $1.2B | ||
| Q3 24 | $7.5B | $985.3M | ||
| Q2 24 | $7.5B | $987.4M | ||
| Q1 24 | $7.4B | $988.4M |
负债/权益比CASHZLAB
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.05× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $108.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $104.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 60.1% | -21.0% |
| 资本支出强度资本支出/营收 | 2.4% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.08× | — |
| 过去12个月自由现金流最近4个季度 | $616.8M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CASHZLAB
| Q4 25 | $108.3M | $-26.0M | ||
| Q3 25 | $303.7M | $-32.0M | ||
| Q2 25 | $30.4M | $-31.0M | ||
| Q1 25 | $188.3M | $-61.7M | ||
| Q4 24 | $-71.7M | $-55.8M | ||
| Q3 24 | $143.1M | $-26.8M | ||
| Q2 24 | $113.2M | $-42.2M | ||
| Q1 24 | $203.0M | $-90.1M |
自由现金流CASHZLAB
| Q4 25 | $104.1M | $-26.7M | ||
| Q3 25 | $300.3M | $-35.0M | ||
| Q2 25 | $27.7M | $-33.9M | ||
| Q1 25 | $184.7M | $-63.2M | ||
| Q4 24 | $-73.8M | $-58.4M | ||
| Q3 24 | $138.8M | $-28.2M | ||
| Q2 24 | $111.0M | $-42.9M | ||
| Q1 24 | $201.3M | $-91.1M |
自由现金流率CASHZLAB
| Q4 25 | 60.1% | -21.0% | ||
| Q3 25 | 160.9% | -30.4% | ||
| Q2 25 | 14.1% | -31.1% | ||
| Q1 25 | 67.2% | -59.9% | ||
| Q4 24 | -40.4% | -53.8% | ||
| Q3 24 | 77.3% | -27.7% | ||
| Q2 24 | 58.8% | -42.9% | ||
| Q1 24 | 78.1% | -104.5% |
资本支出强度CASHZLAB
| Q4 25 | 2.4% | 0.5% | ||
| Q3 25 | 1.8% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 1.3% | 1.5% | ||
| Q4 24 | 1.1% | 2.4% | ||
| Q3 24 | 2.4% | 1.3% | ||
| Q2 24 | 1.2% | 0.7% | ||
| Q1 24 | 0.7% | 1.1% |
现金转化率CASHZLAB
| Q4 25 | 3.08× | — | ||
| Q3 25 | 7.83× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 2.51× | — | ||
| Q4 24 | -2.39× | — | ||
| Q3 24 | 4.27× | — | ||
| Q2 24 | 2.52× | — | ||
| Q1 24 | 2.90× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CASH
| Consumer | $103.0M | 59% |
| Payment Card And Deposit Fees | $30.1M | 17% |
| Other | $24.2M | 14% |
| Rental Income | $11.6M | 7% |
| Commercial | $4.2M | 2% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
